Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00721409 · ClinicalTrials.gov registry record · Phase 2
Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 177
- Enrollment target
NCT00721409 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 177 participants.
The verdict
NCT00721409, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 177 participants
- Enrollment target
Study Summary
The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer
Interventions
- DRUG letrozole
- DRUG PD 0332991
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2008-09-15 |
| Est. Completion | 2017-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00721409
The ClinicalTrials.gov registry entry for NCT00721409 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 177 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which letrozole is the first listed.
NCT00721409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00721409 about?
NCT00721409 is a clinical study titled "Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer". The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer
What is the current status of trial NCT00721409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 177 participants. The study started on 2008-09-15. Estimated completion is 2017-12-20.
What interventions are being tested in trial NCT00721409?
The interventions under investigation include: letrozole (DRUG), PD 0332991 (DRUG).
Who is sponsoring clinical trial NCT00721409?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.